Literature DB >> 34038804

Epigenetic regulation in Huntington's disease.

Jae Wook Hyeon1, Albert H Kim2, Hiroko Yano3.   

Abstract

Huntington's disease (HD) is a devastating and fatal monogenic neurodegenerative disorder characterized by progressive loss of selective neurons in the brain and is caused by an abnormal expansion of CAG trinucleotide repeats in a coding exon of the huntingtin (HTT) gene. Progressive gene expression changes that begin at premanifest stages are a prominent feature of HD and are thought to contribute to disease progression. Increasing evidence suggests the critical involvement of epigenetic mechanisms in abnormal transcription in HD. Genome-wide alterations of a number of epigenetic modifications, including DNA methylation and multiple histone modifications, are associated with HD, suggesting that mutant HTT causes complex epigenetic abnormalities and chromatin structural changes, which may represent an underlying pathogenic mechanism. The causal relationship of specific epigenetic changes to early transcriptional alterations and to disease pathogenesis require further investigation. In this article, we review recent studies on epigenetic regulation in HD with a focus on DNA and histone modifications. We also discuss the contribution of epigenetic modifications to HD pathogenesis as well as potential mechanisms linking mutant HTT and epigenetic alterations. Finally, we discuss the therapeutic potential of epigenetic-based treatments.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DNA methyltransferases (DNMTs); Epigenetic regulation; Epigenetic-based therapy; Huntington's disease (HD); Neurodegeneration; Transcription

Mesh:

Substances:

Year:  2021        PMID: 34038804      PMCID: PMC9110274          DOI: 10.1016/j.neuint.2021.105074

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   4.297


  231 in total

1.  Genetic and Functional Analyses Point to FAN1 as the Source of Multiple Huntington Disease Modifier Effects.

Authors:  Kyung-Hee Kim; Eun Pyo Hong; Jun Wan Shin; Michael J Chao; Jacob Loupe; Tammy Gillis; Jayalakshmi S Mysore; Peter Holmans; Lesley Jones; Michael Orth; Darren G Monckton; Jeffrey D Long; Seung Kwak; Ramee Lee; James F Gusella; Marcy E MacDonald; Jong-Min Lee
Journal:  Am J Hum Genet       Date:  2020-06-25       Impact factor: 11.025

Review 2.  Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Mol Cell Neurosci       Date:  2012-12-05       Impact factor: 4.314

3.  Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease.

Authors:  Kirupa Sathasivam; Andreas Neueder; Theresa A Gipson; Christian Landles; Agnesska C Benjamin; Marie K Bondulich; Donna L Smith; Richard L M Faull; Raymund A C Roos; David Howland; Peter J Detloff; David E Housman; Gillian P Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

4.  Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease.

Authors: 
Journal:  Cell       Date:  2015-07-30       Impact factor: 41.582

Review 5.  Polyglutamine Repeats in Neurodegenerative Diseases.

Authors:  Andrew P Lieberman; Vikram G Shakkottai; Roger L Albin
Journal:  Annu Rev Pathol       Date:  2018-08-08       Impact factor: 23.472

Review 6.  Undercover: gene control by metabolites and metabolic enzymes.

Authors:  Jan A van der Knaap; C Peter Verrijzer
Journal:  Genes Dev       Date:  2016-11-01       Impact factor: 11.361

Review 7.  Writing, erasing and reading histone lysine methylations.

Authors:  Kwangbeom Hyun; Jongcheol Jeon; Kihyun Park; Jaehoon Kim
Journal:  Exp Mol Med       Date:  2017-04-28       Impact factor: 8.718

8.  MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1.

Authors:  Michael Flower; Vilija Lomeikaite; Marc Ciosi; Sarah Cumming; Fernando Morales; Kitty Lo; Davina Hensman Moss; Lesley Jones; Peter Holmans; Darren G Monckton; Sarah J Tabrizi
Journal:  Brain       Date:  2019-06-19       Impact factor: 13.501

9.  Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.

Authors:  Emma Hockly; Victoria M Richon; Benjamin Woodman; Donna L Smith; Xianbo Zhou; Eddie Rosa; Kirupa Sathasivam; Shabnam Ghazi-Noori; Amarbirpal Mahal; Philip A S Lowden; Joan S Steffan; J Lawrence Marsh; Leslie M Thompson; Cathryn M Lewis; Paul A Marks; Gillian P Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

10.  Early alteration of epigenetic-related transcription in Huntington's disease mouse models.

Authors:  Irati Hervás-Corpión; Deisy Guiretti; Manuel Alcaraz-Iborra; Román Olivares; Antonio Campos-Caro; Ángel Barco; Luis M Valor
Journal:  Sci Rep       Date:  2018-07-02       Impact factor: 4.379

View more
  3 in total

1.  Association of DNA methylation with steroidogenic enzymes in Cushing's adenoma.

Authors:  Takaya Kodama; Kenji Oki; Yu Otagaki; Ryuta Baba; Akira Okada; Kiyotaka Itcho; Kazuhiro Kobuke; Gaku Nagano; Haruya Ohno; Nobuyuki Hinata; Koji Arihiro; Celso E Gomez-Sanchez; Masayasu Yoneda; Noboru Hattori
Journal:  Endocr Relat Cancer       Date:  2022-06-29       Impact factor: 5.900

Review 2.  Genotoxic Damage During Brain Development Presages Prototypical Neurodegenerative Disease.

Authors:  Glen E Kisby; Peter S Spencer
Journal:  Front Neurosci       Date:  2021-12-02       Impact factor: 4.677

Review 3.  The emerging role of long non-coding RNAs, microRNAs, and an accelerated epigenetic age in Huntington's disease.

Authors:  Soudeh Ghafouri-Fard; Tayyebeh Khoshbakht; Bashdar Mahmud Hussen; Mohammad Taheri; Kaveh Ebrahimzadeh; Rezvan Noroozi
Journal:  Front Aging Neurosci       Date:  2022-09-15       Impact factor: 5.702

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.